Search results for "Aβ"

showing 8 items of 18 documents

Lipofuscin Hypothesis of Alzheimer’s Disease

2011

The primary culprit responsible for Alzheimer’s disease (AD) remains unknown. Aβ protein has been identified as the main component of amyloid of senile plaques, the hallmark lesion of AD, but it is not definitively established whether the formation of extracellular Aβ deposits is the absolute harbinger of the series of pathological events that hit the brain in the course of sporadic AD. The aim of this paper is to draw attention to a relatively overlooked age-related product, lipofuscin, and advance the hypothesis that its release into the extracellular space following the death of neurons may substantially contribute to the formation of senile plaques. The presence of intraneuronal Aβ, sim…

Aβ proteinNeurofibrillary tanglesAmyloidAmyloidCognitive Neurosciencelcsh:Geriatricslcsh:RC346-429LipofuscinLipofuscinLesionExtracellularMedicineOriginal Research ArticleSenile plaquesPathologicallcsh:Neurology. Diseases of the nervous systembusiness.industryMacular degenerationAlzheimer's diseaseMacular degenerationmedicine.diseaseBiochemistry of Alzheimer's diseaselcsh:RC952-954.6Psychiatry and Mental healthmedicine.symptombusinessAlzheimer’s diseaseNeuroscienceDementia and Geriatric Cognitive Disorders Extra
researchProduct

Progressive effect of beta amyloid peptides accumulation on CA1 pyramidal neurons: a model study suggesting possible treatments

2012

Several independent studies show that accumulation of β-amyloid (Aβ) peptides, one of the characteristic hallmark of Alzheimer's Disease (AD), can affect normal neuronal activity in different ways. However, in spite of intense experimental work to explain the possible underlying mechanisms of action, a comprehensive and congruent understanding is still lacking. Part of the problem might be the opposite ways in which Aβ have been experimentally found to affect the normal activity of a neuron; for example, making a neuron more excitable (by reducing the A- or DR-type K(+) currents) or less excitable (by reducing synaptic transmission and Na(+) current). The overall picture is therefore confus…

Computational modelion channels modulationAmyloidMechanism (biology)Model studyNeuroscience (miscellaneous)A?-peptideNeurotransmissionBiologyAlzheimer's diseaselcsh:RC321-571Cellular and Molecular Neurosciencemedicine.anatomical_structureAβ-peptidehippocampal neuronmedicinePremovement neuronal activityrealistic modelNeuronOriginal Research ArticleBeta (finance)Neurosciencelcsh:Neurosciences. Biological psychiatry. NeuropsychiatryNeuroscience
researchProduct

Conical nanopores highlight the pro-aggregating effects of pyrimethanil fungicide on Aβ(1-42) peptides and dimeric splitting phenomena.

2022

International audience; The Aβ(1-42) aggregation is a key event in the physiopathology of Alzheimer's disease (AD). Exogenous factors such as environmental pollutants, and more particularly pesticides, can corrupt Aβ(1-42) assembly and could influence the occurrence and pathophysiology of AD. However, pesticide involvement in the early stages of Aβ(1-42) aggregation is still unknown. Here, we employed conical track-etched nanopore in order to analyse the Aβ(1-42) fibril formation in the presence of pyrimethanil, a widely used fungicide belonging to the anilinopyrimidine class. Our results evidenced a pro-aggregating effect of pyrimethanil on Aβ(1-42). Aβ(1-42) assemblies were successfully d…

Environmental EngineeringAmyloidHealth Toxicology and MutagenesisDimerSettore ING-IND/06track-etchedMolecular dynamicschemistry.chemical_compoundNanoporesFibril formationPEG ratio[CHIM] Chemical SciencesfungicideEnvironmental Chemistry[CHIM]Chemical SciencesnanoporeAmyloid beta-PeptidesChemistryPublic Health Environmental and Occupational HealthamyloidGeneral MedicineGeneral ChemistryPollutionresistive pulsePeptide FragmentsAβ(1-42)Fungicides IndustrialNanoporePyrimidinesAβ(1–42)Biophysicslag phasePyrimethanilChemosphere
researchProduct

A New Tool for the Analysis of the Effect of Intracerebrally Injected Anti-Amyloid-β Compounds

2021

Background: A wide range of techniques has been developed over the past decades to characterize amyloid-β (Aβ) pathology in mice. Until now, no method has been established to quantify spatial changes in Aβ plaque deposition due to targeted delivery of substances using ALZET® pumps. Objective: Development of a methodology to quantify the local distribution of Aβ plaques after intracerebral infusion of compounds. Methods: We have developed a toolbox to quantify Aβ plaques in relation to intracerebral injection channels using Zeiss AxioVision® and Microsoft Excel® software. For the proof of concept, intracerebral stereotactic surgery was performed in 50-day-old APP-transgenic mice injected wit…

Intracerebral injectionAmyloid βMice TransgenicPlaque Amyloidamyloid-βtransgenic miceStereotaxic TechniqueshistologyMiceAlzheimer DiseaseAnimalsHumansDistribution (pharmacology)implantable infusion pumpdistributional activityAmyloid beta-PeptidesChemistryGeneral NeuroscienceBrainGeneral MedicineImmunohistochemistryplaquesAβ depositionquantificationDisease Models AnimalPsychiatry and Mental healthClinical PsychologyGeriatrics and GerontologyAlzheimer’s diseaseResearch ArticleBiomedical engineeringJournal of Alzheimer's Disease
researchProduct

Systemic Immune Responses in Alzheimer's Disease: In Vitro Mononuclear Cell Activation and Cytokine Production

2010

To investigate the systemic signs of immune-inflammatory responses in Alzheimer's disease (AD), in the present study we have analyzed blood lymphocyte subsets and the expression of activation markers on peripheral blood mononuclear cells (PBMCs) from AD patients and age-matched healthy controls (HC) activated in vitro by recombinant amyloid-beta peptide (rAbeta42). Our study of AD lymphocyte subpopulations confirms the already described decrease of the absolute number and percentage of B cells when compared to HC lymphocytes, whereas the other subsets are not significantly different in patients and controls. We report the increased expression of the activation marker CD69 and of the chemoki…

MaleEotaxinCCR2ChemokineTime Factorsmedicine.medical_treatmentPeripheral blood mononuclear cellChemokine receptorImmune systemAlzheimer’s disease chemokine cytokine PBMC rAβ42Alzheimer DiseasemedicineHumansLymphocytesIL-2 receptorCells CulturedAgedSettore MED/04 - Patologia GeneraleAged 80 and overAnalysis of VarianceAmyloid beta-Peptidesbiologybusiness.industryGeneral NeuroscienceGeneral MedicineMiddle AgedFlow CytometryPeptide FragmentsPsychiatry and Mental healthClinical PsychologyCytokineGene Expression RegulationCase-Control StudiesImmunologyLeukocytes Mononuclearbiology.proteinCytokinesFemaleGeriatrics and GerontologybusinessJournal of Alzheimer's Disease
researchProduct

P3–200: Relationship between neurofibrillary pathology and Aβ deposition in Alzheimer disease

2006

Pathologymedicine.medical_specialtyEpidemiologybusiness.industryHealth Policymedicine.diseaseAβ depositionPsychiatry and Mental healthCellular and Molecular NeuroscienceDevelopmental NeurosciencemedicineNeurology (clinical)Geriatrics and GerontologyAlzheimer's diseasebusinessAlzheimer's & Dementia
researchProduct

Thioflavin T templates amyloid β(1–40) conformation and aggregation pathway

2015

Aβ(1-40) peptide supramolecular assembly and fibril formation processes are widely recognized to have direct implications in the progression of Alzheimer's disease. The molecular basis of this biological process is still unknown and there is a strong need of developing effective strategies to control the occurring events. To this purpose the exploitation of small molecules interacting with Aβ aggregation represents one of the possible routes. Moreover, the use specific labeling has represented so far one of the most common and effective methods to investigate such a process. This possibility in turn rests on the reliability of the probe/labels involved. Here we present evidences of the effe…

Protein StructureSecondaryAβ(1–40) peptideAmyloidProtein ConformationMolecular Sequence DataBiophysicsSupramolecular chemistryMolecular Dynamics SimulationProtein aggregationProtein Aggregation PathologicalBiochemistryProtein Structure SecondarySupramolecular assemblyProtein Aggregateschemistry.chemical_compoundProtein structureAlzheimer DiseasePathologicalSecondary structureAβ(1-40) peptideHumansBenzothiazolesAmino Acid SequenceFluorescent DyesAmyloid beta-PeptidesProtein StabilityOrganic ChemistryAlzheimer's diseaseProtein AggregationSmall moleculePeptide FragmentsSettore FIS/07 - Fisica Applicata(Beni Culturali Ambientali Biol.e Medicin)Peptide ConformationAlzheimer's disease; Aβ(1–40) peptide; Protein aggregation; Protein conformation; Secondary structure; Thioflavin T; Alzheimer Disease; Amino Acid Sequence; Amyloid beta-Peptides; Fluorescence Recovery After Photobleaching; Fluorescent Dyes; Humans; Molecular Dynamics Simulation; Molecular Sequence Data; Peptide Fragments; Protein Aggregates; Protein Aggregation Pathological; Protein Conformation; Protein Multimerization; Protein Stability; Protein Structure Secondary; ThiazolesThiazolesBiophysicBiochemistrychemistryThioflavin TBiophysicsThioflavinProtein MultimerizationFluorescence Recovery After PhotobleachingBiophysical Chemistry
researchProduct

The deubiquitinase USP11 is a versatile and conserved regulator of autophagy

2021

Autophagy is a major cellular quality control system responsible for the degradation of proteins and organelles in response to stress and damage to maintain homeostasis. Ubiquitination of autophagy-related proteins or regulatory components is important for the precise control of autophagy pathways. Here, we show that the deubiquitinase ubiquitin-specific protease 11 (USP11) restricts autophagy and that KO of USP11 in mammalian cells results in elevated autophagic flux. We also demonstrate that depletion of the USP11 homolog H34C03.2 in Caenorhabditis elegans triggers hyperactivation of autophagy and protects the animals against human amyloid-β peptide 42 aggregation-induced paralysis. USP11…

autophagyhAβ42 human amyloid-β protein 1 to 42Lipid kinase activityPI(3)P phosphatidylinositol-3-phosphatemTORC1BiochemistryCell LineGene Knockout Techniqueschemistry.chemical_compoundubiquitinAnimalsHumansULK1 unc-51-like autophagy activating kinase 1WIPI WD-repeat domain phosphoinositide-interacting proteinPI3KC3-C1Caenorhabditis elegansCaenorhabditis elegans ProteinsmTORC1Molecular BiologyMechanistic target of rapamycinUSP11 ubiquitin-specific protease 11proteostasisAmyloid beta-PeptidesS6K S6 kinasebiologyPhosphatidylinositol 3-phosphateAutophagyDUB deubiquitinaseLFQ label-free quantificationIP immunoprecipitationNHT nonhuman targetingPI3KC3-C1 class III phosphatidylinositol 3-kinase complex ICell BiologyACN acetonitrile amyloid-βNRBF2 nuclear receptor-binding factor 2Peptide FragmentsCell biologydeubiquitinase (DUB)ProteostasischemistryProteotoxicitymTORC1 mechanistic target of rapamycin complex 1biology.proteinAutophagy-Related Protein-1 HomologBSA bovine serum albuminThiolester HydrolasesResearch ArticleJournal of Biological Chemistry
researchProduct